SCHEMBL6202441

SCHEMBL6202441

CCNc1ccc(CN2CCOCC2)cc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
POLB P06746 1/20 0.54
PKM P14618 1/20 0.54
LMNA P02545 4/20 0.53
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KCNJ1 P48048 2/20 0.53
TDP1 Q9NUW8 3/20 0.51
RAB9A P51151 1/20 0.50
KDM4E B2RXH2 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 1/20 0.48
HCAR3 P49019 1/20 0.48
KMT2A Q03164 2/20 0.44
KAT2B Q92831 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5238748 0.88 ALDH1A1 (0.56) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL5471056 0.85 MAPT (0.65) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL546450 0.84 ALDH1A1 (0.64) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL30061320 0.84 ALDH1A1 (0.64) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL26234109 0.81 MAPT (0.64) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL16054038 0.81 ALDH1A1 (0.59) MAPTPOLBPKMLMNAALDH1A1
SCHEMBL6609950 0.80 MAPT (0.56) MAPTPOLBLMNAALDH1A1SMN1; SMN2
SCHEMBL11367032 0.79 ATM (0.48) MAPTPKMLMNAALDH1A1SMN1; SMN2
SCHEMBL24290490 0.78 NCF1 (0.48) MAPTALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL21600747 0.78 ALDH1A1 (0.63) MAPTPOLBLMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507776-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS Amgen Inc. (US) 2005-02-23 EP disclosed
WO-2003101985-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS AMGEN INC. (US) 2003-12-11 WO disclosed